Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00132041 · ClinicalTrials.gov registry record · NA
Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
A NA study, sponsored by American College of Radiology Imaging Network.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT00132041: Completed NA study, sponsored by American College of Radiology Imaging Network.
NCT00132041 is a NA study that has completed, run by American College of Radiology Imaging Network. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00132041, a NA study, has completed, sponsored by American College of Radiology Imaging Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. CT-, MRI-, or ultrasound-guided radiofrequency ablation may be an effective treatment for liver cancer and cirrhosis. PURPOSE: This phase II trial is studying how well radiofrequency ablation works in treating patients with liver cancer and cirrhosis.
Primary Outcome
Outcome is positive (success) if alive and no disease is observed by CT at 18 months post start of therapy Outcome is negative if the patient was deceased or disease was observed by CT at 18 months post start of therapy Success rate it the fraction of eligible patients who were alive and disease free at 18 months.
Interventions
- DEVICE radiofrequency ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-11 |
| Phase | NA |
What the finished NCT00132041 record still lists
NCT00132041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which radiofrequency ablation is the first listed.
NCT00132041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00132041 about?
NCT00132041 is a clinical study titled "Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis". RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. CT-, MRI-, or ultrasound-guided radiofrequency ablation may be an effective treatment for liver cancer and cirrhosis. PURPOSE: This phase II trial is studying how well radiofrequency ablation works in tr...
What is the current status of trial NCT00132041?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2005-12. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00132041?
The interventions under investigation include: radiofrequency ablation (DEVICE).
Who is sponsoring clinical trial NCT00132041?
This trial is sponsored by American College of Radiology Imaging Network, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00132041's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia